Calf Augmentation in Toronto CA
This procedure offers a solution for those people that have underdeveloped calves or wish to augment them. The idea is to shape and size the calves by surgical insertion of implants. The implants are made of soft silicon and they come in different shapes and sizes. Before the operation your legs will be measured to select a proper implant for your needs. There is an alternative to implants. Calf augmentation can also be performed by liposuction of fat from other body parts and injecting it into the calves. This method is not suitable for people with no extra fat to be removed. Another problem is fat absorption that eventually occurs, sometimes creating not symmetric calves. Men and women can benefit from this procedure. Men usually want to increase the muscle bulk, giving them more masculine look and women wish to get more symmetrical appearance of their legs. This procedure also may help to correct some congenital defects, those include polio, spina bifida and clubfoot, all this conditions may be associated with undeveloped calves.
This procedure can be done with local or general anesthesia, and it usually lasts for an hour. During the operation the patient is laying on their back. A cut is made in the concavity behind the knee, then the skin is gently separated and a space is created. The implant is inserted above the muscles. After one leg is done the doctor performs the same on the other one. After the symmetry is confirmed the surgeon closes the cuts with stitches.
Every operation has its ricks. This one includes bleeding, infection and sometimes implants shrinkage and asymmetry.
After the surgery you may feel some degree of pain. Your doctor'll subscribe you for painkillers. At the first two days you'll be asked to raise your legs whenever you are sitting, this to reduce swelling. Afterwards, the bandages are removed and you are encouraged to walk more intensively to train your calve muscles. For about two weeks you'll fell like you're calves is been through excessive workout. Swelling and bruising also may appear, they are only temporary and will improve with time. You'll be able to go back to work after 7-10 days. You'll get detailed instructions from you're surgeon regarding the activities you should avoid, for example long walking, weight lifting and running. Usually, most of the patients are able to return to their daily activities after 4-6 weeks.
More Toronto info...
Toronto Tokens vs. Tickets
If you have decided not to purchase a daily pass (and they are an excellent option for those who intend to use transit a lot, especially for families), you may want to purchase tokens instead of tickets. They're equally valid at collector's booths and when boarding busses/streetcars, but the TTC also offers separate and automated token and metropass-only turnstiles at all stations which are often much quicker than waiting for the queue in front of the collector's booth to clear.
Tickets may be purchased from many convenience stores (look for a TTC sign in the front window) and a few hotel desks as well as collector's booths at any subway station. Tokens may be purchased from vending machines in stations and from collectors. Bus and streetcar drivers do not offer change and do not sell tickets or tokens.
-
Toronto Climate
It gets very cold during the winter and very hot and muggy in the summer. Fall is the best season. Toronto's public buildings are air-conditioned in summer and heated in winter.
[edit] -
Plastic Surgery News...
- A ‘blog’ produced by the National Prescribing Centre (NPC) and posted on its website (NPCi) discusses QRISK – a new cardiovascular disease risk scoring system that was developed specifically for use in the UK. A validation study for this system was published recently in the journal ‘Heart’; the study abstract and the calculator itself can be accessed via the links above.
The blog discusses the calculator and the validation study, and discusses its place in comparison with the Framingham method in predicting cardiovascular risk in the general population. The author of the blog concludes (taken directly from the website):
“Health professionals should be aware of the ongoing debate, and also that Framingham-based tools may over-predict CV risk in some sections of the UK population, but not others, such as those in high risk groups (e.g. socio-economically deprived, people of South Asian descent, those with a family history of CV events, etc). Even with these caveats, as the draft NICE full guideline on lipid modification says - estimates of CVD risk derived from equations are not an exact science but are better than clinical judgment alone for the estimation of CVD risk. Of course, health professionals need to take into account patient circumstances and wishes. It would be foolish to have an iron rule that (whatever tool is used) someone with a 19.9% predicted risk can never receive prophylaxis, but someone with a 20.1% risk must always receive prophylaxis. The most important thing is to correctly use a validated tool – be it Framingham, ASSIGN or QRISK as a basis for discussion with patients and not to treat on the basis of individual risk factors.”
- The Annals of Internal Medicine have featured guidelines on the current pharmacological treatment of dementia as published by the American College of Physicians and American Academy of Family Physicians.
The review in the Annals discusses dementia related to Alzheimer’s disease and vascular dementia, and discusses the evidence for approved pharmacological therapies, for outcomes in the domains of cognition, global function, behaviour/mood, and quality of life/activities of daily living. The guidelines conclude with the following recommendations (as taken directly from source):
Recommendation 1: Clinicians should base the decision to initiate a trial of therapy with a cholinesterase inhibitor or memantine on individualised assessment. (Grade: weak recommendation, moderate-quality evidence.)
Recommendation 2: Clinicians should base the choice of pharmacological agents on tolerability, adverse effect profile, ease of use, and cost of medication. The evidence is insufficient to compare the effectiveness of different pharmacological agents for the treatment of dementia. (Grade: weak recommendation, low-quality evidence.)
Recommendation 3: There is an urgent need for further research on the clinical effectiveness of pharmacological management of dementia.
The Annals also features a related review of the literature discussing the evidence for the effectiveness of cholinesterase inhibitors (donepezil, galantamine, rivastigmine, and tacrine) and the neuropeptide-modifying agent memantine in achieving clinically relevant improvements, primarily in cognition, global function, behaviour, and quality of life, for patients with dementia. This review forms the basis of the guidelines.